bispecific antibodies

Major study data to look out for from ASH 2020 1:55
Major study data to look out for from ASH 2020
John Gribben • 20 Nov 2020
Immuno-oncology and the future of multiple myeloma treatment 2:22
Immuno-oncology and the future of multiple myeloma treatment
Jesus San Miguel • 16 Dec 2020
Multiple myeloma highlights from ASH 2020 3:59
Multiple myeloma highlights from ASH 2020
Luciano Costa • 6 Dec 2020
SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma 3:30
SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma
Alexander Lesokhin • 4 Dec 2020
Phase I trial of a FcRH5-targeted BiTE in R/R myeloma 6:44
Phase I trial of a FcRH5-targeted BiTE in R/R myeloma
Adam Cohen • 10 Dec 2020
Latest updates in myeloma: key takeaways from ASH 2020 5:13
Latest updates in myeloma: key takeaways from ASH 2020
Daniel Auclair • 15 Dec 2020
Mosunetuzumab for chemotherapy-intolerant DLBCL 2:52
Mosunetuzumab for chemotherapy-intolerant DLBCL
Adam Olszewski • 8 Dec 2020
Approved and emerging antibody-based therapies in myeloma 2:22
Approved and emerging antibody-based therapies in myeloma
Alexander Lesokhin • 4 Dec 2020
Highlights in lymphoma at ASH 2020 2:08
Highlights in lymphoma at ASH 2020
Deepa Jagadeesh • 7 Dec 2020
Flotetuzumab for primary induction failure & early relapse AML 5:04
Flotetuzumab for primary induction failure & early relapse AML
John DiPersio • 8 Dec 2020
Updates at ASH 2020 on bispecific antibodies in MM 1:55
Updates at ASH 2020 on bispecific antibodies in MM
Joshua Richter • 4 Dec 2020
Talquetamab: GPRC5D-CD3 bispecific antibody in R/R myeloma 4:15
Talquetamab: GPRC5D-CD3 bispecific antibody in R/R myeloma
Maria-Victoria Mateos • 1 Dec 2020
The future of multiple myeloma treatment 1:53
The future of multiple myeloma treatment
Joseph Mikhael • 21 Oct 2020
The future of immunotherapies for multiple myeloma 4:38
The future of immunotherapies for multiple myeloma
Luciano Costa • 3 Oct 2020
The benefits of bispecific antibodies for treating multiple myeloma 6:34
The benefits of bispecific antibodies for treating multiple myeloma
Luciano Costa • 3 Oct 2020
The future of CAR T-cells and bispecific antibodies to treat myeloma 1:13
The future of CAR T-cells and bispecific antibodies to treat myeloma
Sagar Lonial • 30 Sep 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals